NASDAQ:ATYR aTyr Pharma (ATYR) Stock Price, News & Analysis $0.49 0.00 (-0.10%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$0.50 +0.01 (+2.49%) As of 06:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About aTyr Pharma Stock (NASDAQ:ATYR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get aTyr Pharma alerts:Sign Up Key Stats Today's Range$0.48▼$0.5150-Day Range$0.40▼$0.6552-Week Range$0.40▼$7.29Volume861,914 shsAverage Volume2.32 million shsMarket Capitalization$47.64 millionP/E RatioN/ADividend YieldN/APrice Target$17.00Consensus RatingHold Company Overview aTyr Pharma, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors. The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling. Its lead program, ATYR1923, is being investigated for the treatment of pulmonary sarcoidosis, and additional pipeline candidates are advancing in preclinical and early clinical studies for oncology and neuromuscular disorders. aTyr’s platform allows for the rapid screening of protein interactions and the engineering of modulators with potential applications across multiple therapeutic areas. Founded in 2005, aTyr Pharma completed its initial public offering in 2015 and has since entered into strategic collaborations to accelerate the development and potential commercialization of its product candidates. The company’s research and development activities span North America and Europe, and its leadership team brings together expertise in protein therapeutics, immunology, and clinical development. aTyr continues to leverage its platform to address unmet medical needs and to expand its pipeline through internal discovery and external partnerships.AI Generated. May Contain Errors. Read More aTyr Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreATYR MarketRank™: aTyr Pharma scored higher than 69% of companies evaluated by MarketBeat, and ranked 441st out of 1,682 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingaTyr Pharma has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 strong buy rating, 1 buy rating, 5 hold ratings, and 1 sell rating.Upside PotentialaTyr Pharma has a consensus price target of $17.00, representing about 3,398.7% upside from its current price of $0.49.Amount of Analyst CoverageaTyr Pharma has only been the subject of 2 research reports in the past 90 days.Read more about aTyr Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for aTyr Pharma are expected to decrease in the coming year, from ($0.66) to ($0.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of aTyr Pharma is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of aTyr Pharma is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioaTyr Pharma has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about aTyr Pharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted15.70% of the float of aTyr Pharma has been sold short.Short Interest Ratio / Days to CoveraTyr Pharma has a short interest ratio ("days to cover") of 5.07.Change versus previous monthShort interest in aTyr Pharma has recently decreased by 21.64%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldaTyr Pharma does not currently pay a dividend.Dividend GrowthaTyr Pharma does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.50 News SentimentaTyr Pharma has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for aTyr Pharma this week, compared to 8 articles on an average week.Search InterestOnly 2 people have searched for ATYR on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows5 people have added aTyr Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership3.8 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $50,000.00 in company stock, which represents 0.1049% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, aTyr Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders5.75% of the stock of aTyr Pharma is held by insiders.Percentage Held by Institutions61.72% of the stock of aTyr Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about aTyr Pharma's insider trading history. Receive ATYR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATYR Stock News HeadlinesAnalysts Conflicted on These Healthcare Names: aTyr Pharma (ATYR), Kymera Therapeutics (KYMR) and Cannara Biotech (OtherLOVFF)July 17, 2026 | theglobeandmail.comaTyr Pharma Reports Clinically Meaningful FVC Benefit in Restrictive Lung Disease Subgroup of EFZO-FIT Study of EfzofitimodJuly 15, 2026 | quiverquant.comQOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warning for AI investors - and a specific prediction about what the number-one investment of the next decade will be. Green started his career on Wall Street four decades ago and retired in his 40s. He believes a major shift in the AI trade is coming - and that most investors won't hear about it until it's too late.July 22 at 1:00 AM | The Oxford Club (Ad)aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026July 15, 2026 | globenewswire.comAnalysts Conflicted on These Healthcare Names: Tilray (TLRY) and aTyr Pharma (ATYR)July 15, 2026 | theglobeandmail.comaTyr Pharma Stock Short Interest Report | NASDAQ:ATYR | BenzingaJuly 12, 2026 | benzinga.comAnalysts Offer Insights on Healthcare Companies: aTyr Pharma (ATYR) and CG Oncology, Inc. (CGON)July 11, 2026 | theglobeandmail.comaTyr Pharma Refines Efzofitimod Strategy After Phase 2 DataJuly 7, 2026 | theglobeandmail.comSee More Headlines ATYR Stock Analysis - Frequently Asked Questions How have ATYR shares performed this year? aTyr Pharma's stock was trading at $0.7831 at the beginning of 2026. Since then, ATYR stock has decreased by 38.0% and is now trading at $0.4859. How were aTyr Pharma's earnings last quarter? aTyr Pharma, Inc. (NASDAQ:ATYR) issued its quarterly earnings data on Friday, May, 15th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.05. When did aTyr Pharma IPO? aTyr Pharma (ATYR) raised $75 million in an IPO on Thursday, May 7th 2015. The company issued 5,360,000 shares at a price of $13.00-$15.00 per share. How do I buy shares of aTyr Pharma? Shares of ATYR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of aTyr Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that aTyr Pharma investors own include ChargePoint (CHPT), Plug Power (PLUG), Chemomab Therapeutics (CMMB), Curaleaf (CURLF), Dare Bioscience (DARE), Jiuzi (JZXN) and Adial Pharmaceuticals (ADIL). Company Calendar Last Earnings5/15/2026Today7/22/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 ATYR's financial health is in the Red zone, according to TradeSmith. ATYR has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATYR Previous SymbolNASDAQ:ATYR CIK1339970 WebN/A Phone(858) 731-8389Fax858-731-8394Employees53Year Founded2005Price Target and Rating Average Price Target for aTyr Pharma$17.00 High Price Target$17.00 Low Price Target$17.00 Potential Upside/Downside+3,398.7%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.12 million Net MarginsN/A Pretax Margin-36,860.00% Return on Equity-100.14% Return on Assets-73.55% Debt Debt-to-Equity RatioN/A Current Ratio5.78 Quick Ratio5.78 Sales & Book Value Annual Sales$190 thousand Price / Sales250.75 Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book0.70Miscellaneous Outstanding Shares98,050,000Free Float92,413,000Market Cap$47.64 million OptionableOptionable Beta0.52 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:ATYR) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...Stansberry Research | SponsoredWhat most options traders never learn before their first tradeMost options losses don't come from picking the wrong trade - they come from traders who never understood how ...Base Camp Trading | SponsoredThis tiny piece of glass could be bigger than GPUsJensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...Brownstone Research | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | Sponsored30-Year market veteran reveals America’s #1 StockMarket veteran Jim Woods has flagged triple-digit gains multiple times in under two months - 151% on Netflix, ...Eagle Publishing | SponsoredForget SpaceX… this is the REAL #1 IPO of 2026While SpaceX and OpenAI dominate IPO headlines, one private company is reportedly seeing the fastest revenue g...The Oxford Club | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share aTyr Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
